Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes 2024 2025 Oral semaglutide found to lower risk of heart failure events in people with type 2 diabetes orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes 2024 2025 Oral semaglutide found to lower risk of heart failure events in people with type 2 diabetes ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes 2024 2025 Oral semaglutide found to lower risk of heart failure events in people with type 2 diabetes, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes 2024 2025 Oral semaglutide found to lower risk of heart failure events in people with type 2 diabetes in your area.
SOUL (Semaglutide cardiOvascular oUtcomes triaL) in individuals with
26.06
Oral Semaglutide in High-Risk Type 2 Diabetes: Cardiovascular Benefit Confirmed in the SOUL Trial
24.43
The SOUL trial (Semaglutide Cardiovascular Outcomes Trial) was a randomized, double-blind, placebo-controlled cardiovascular outcomes trial that enrolled 9,650 patients aged 50 years or older with
25.55
At ADA 2025, the SOUL trial revealed that oral semaglutide (Rybelsus) reduced the risk of major cardiovascular events—like heart attack, stroke, and CV death—by 14% over ~4 years in type 2 diabetes
29.93
Journal club: SOUL Study – CVOT for Oral Semaglutide Full Title: Cardiovascular Outcomes Trial of Oral Semaglutide in Subjects with Type 2 Diabetes กองอายุรกรรม รพ พระมงกุฎเกล้า
21.18
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
23.71
Trial Scorecard: SOUL
29.95
